Novartis Pharmaceuticals Corp. v. Handa Pharmaceuticals, Inc.

Case Overview: Novartis Pharmaceuticals Corp. v. Handa Pharmaceuticals, Inc. (D. Del., No. 1:22-cv-00352-GBW)

Parties and the accused product. Novartis Pharmaceuticals Corp. is a practicing (operating) pharmaceutical company—the holder of NDA No. 022527 for Gilenya® (fingolimod HCl capsules, 0.5 mg), the first oral therapy approved for relapsing forms of multiple sclerosis. The defendants are four affiliated entities of Taiwan-headquartered Handa Pharmaceuticals: Handa Pharmaceuticals, Inc. (global R&D), Handa Pharma, Inc. (business/IP/regulatory), Handa Pharmaceuticals, LLC (generics), and Handa Neuroscience, LLC (brand/neuroscience and the NDA sponsor), which share a San Jose, California office and are controlled by founder Dr. Fangyu Liu (RPX/paragraphfour copies of the complaint; D.I. 7 corrected complaint). The accused product is Handa's HND-020—fingolimod lauryl sulfate orally disintegrating tablets, 0.5 mg, submitted as § 505(b)(2) NDA No. 214962 on December 18, 2020, with a § 505(b)(2)(A)(iv) certification that the asserted patents were invalid, unenforceable, and/or not infringed. Because Handa's product uses a different salt and dosage form than Gilenya, the fight centered on Novartis's method-of-use claims rather than composition claims.

Patents and procedural posture. The complaint (filed as a corrected complaint, D.I. 7) asserted two Orange Book patents—U.S. Patent No. 9,187,405 ("S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis," issued Nov. 17, 2015), whose claims cover orally administering fingolimod at 0.5 mg/day "absent an immediately preceding loading dose regimen" to reduce relapses, treat RRMS, or slow progression (claims 1, 3, 5; dependent claims 2, 4, 6 add the HCl salt), and U.S. Patent No. 10,543,179 ("Dosage Regimen of an S1P Receptor Modulator," issued Jan. 28, 2020), whose claims cover testing an RRMS patient for varicella zoster virus (VZV) history, vaccinating at-risk patients, and then giving fingolimod 0.5 mg/day. Procedurally, this docket number is itself a venue artifact: Novartis filed parallel suits—the "primary" Delaware case (1:21-cv-00645, filed May 4, 2021, before Judge Stark, later reassigned to Judge Noreika) and a protective "safety suit" in the Northern District of California (3:21-cv-03397-EJD, filed May 6, 2021, before Judge Edward Davila) to preserve the Hatch-Waxman 30-month stay in case venue failed (D.I. 47 memo opinion, 3/1/22). Judge Stark denied Handa's motion to dismiss/transfer to its California "nerve center," and the California case was transferred to Delaware on March 21, 2022, becoming 1:22-cv-00352, assigned to Judge Gregory B. Williams (consent judgment caption "1-22-cv-00352-GBW"; DocketAlarm). Delaware is the nation's dominant Hatch-Waxman forum, and the Gilenya patent war was already heavily litigated there. The case terminated October 26, 2022, when the court entered a stipulated consent judgment (dated Oct. 24, 2022): Handa stipulated that all asserted claims of both patents are valid, enforceable, and infringed by NDA 214962; Novartis granted a license; the judgment was expressly made a "consent decree" under 21 U.S.C. § 355(c)(3)(C)(i)(II) to permit FDA final approval; and Handa was enjoined from launching before a confidential "Generic Entry Date" (paragraphfour.com copy of the proposed consent judgment).

Why the case matters. This was one front of Novartis's decade-long defense of the Gilenya franchise, and its settlement timing makes it notable. The '405 patent had survived PTAB IPR (Apotex Inc. v. Novartis A.G., IPR2017-00854, FWD July 11, 2018) and a Delaware bench trial in Novartis v. Accord/HEC (No. 18-1043-KAJ), which found the claims valid and infringed (final judgment Sept. 11, 2020); the Federal Circuit affirmed on Jan. 4, 2022, but on panel rehearing on June 21, 2022—while the Handa cases were in active claim construction—the Federal Circuit reversed and held the '405 claims invalid for inadequate written description of the negative "no loading dose" limitation. Handa immediately pressed that authority (supplemental-authority letter, D.I. 88, June 22, 2022, and a request for leave to move for summary judgment on the '405 patent, D.I. 92, June 28, 2022). Yet within four months the parties settled with Handa stipulating to validity and infringement of both patents—including the '405 patent the Federal Circuit had just invalidated in a parallel case—and to an injunction tied to a confidential generic-entry date. The case also illustrates the protective-suit strategy brand companies use to preserve Hatch-Waxman stays, and the use of a consent decree to unblock FDA final approval of a 505(b)(2) product. One caveat: the case metadata lists only the '405 patent, but the operative complaint and consent judgment show both the '405 and '179 patents were actually in suit; I found no evidence Handa itself filed IPR petitions on either patent, and the § 355(c)(3)(C)(i)(II) "Generic Entry Date" and settlement economics remain confidential.

Key Legal Developments and Outcome — Novartis Pharmaceuticals Corp. v. Handa Pharmaceuticals, Inc. (D. Del. 1:22-cv-00352-GBW)

Important framing: this case is one of a three-front Hatch-Waxman battle

The docket number in the case metadata (1:22-cv-00352, filed 2022-03-21) is, on the evidence available, the Delaware case number assigned after the Northern District of California "safety suit" was transferred to Delaware on 2022-03-21. The original N.D. Cal. action was Novartis Pharms. Corp. v. Handa Neuroscience, LLC, No. 5:21-cv-03397 (N.D. Cal.), filed 2021-05-06 (DocketAlarm; Unicourt; CourtListener transfer entries). The companion "main" Delaware case is Novartis Pharms. Corp. v. Handa Neuroscience, LLC, No. 1:21-cv-00645 (D. Del.), filed 2021-05-04, which was case-managed together with related Gilenya ANDA litigation (docket references to C.A. No. 1:20-cv-00133-GBW appear throughout). Both Delaware cases asserted U.S. Patent Nos. 9,187,405 (the '405 dosing-regimen patent, at issue here) and 10,543,179 (the '179 patent) against four Handa entities — Handa Neuroscience, LLC (NDA sponsor), Handa Pharmaceuticals, Inc. (Taiwan parent), Handa Pharma, Inc., and Handa Pharmaceuticals, LLC — based on Handa's 505(b)(2) NDA No. 214962 for TASCENSO ODT (HND-020), fingolimod orally disintegrating tablets 0.5 mg, a reformulation of Novartis's Gilenya® (complaint allegations, RPX/paragraphfour PDFs; Novartis v. Handa Neuroscience, D.I. 47, D. Del. 2022-03-01).

---

1. Filing and initial pleadings

• 2021-05-04 — Novartis filed the primary Delaware complaint, 1:21-cv-00645, under the Hatch-Waxman and Declaratory Judgment Acts asserting the '405 and '179 patents against all four Handa entities. The case was assigned to Judge Leonard P. Stark (D.I. 47 caption "1:21-cv-00645-LPS").
• 2021-05-06 — Novartis filed the parallel N.D. Cal. complaint (5:21-cv-03397) as a "safety suit" to preserve the Hatch-Waxman automatic 30-month stay "regardless of the resolution of any venue dispute here in Delaware" (Stark opinion, D.I. 47 at 3). Docket entries show an erroneous original complaint (D.I. 1), errata (D.I. 6), and a corrected complaint (D.I. 7) filed 2021-05-06.
• 2022-03-21 — The N.D. Cal. action was transferred to Delaware and docketed as 1:22-cv-00352 (DocketAlarm: "Filed March 21, 2022 … Terminated Oct. 26, 2022"; Unicourt: "[Transferred from California Northern on 3/21/2022]"). Judge Gregory B. Williams was the assigned district judge for the Delaware phase (DocketAlarm; consent-judgment caption "1-22-cv-00352-GBW").
• Answers/counterclaims — Handa answered and asserted counterclaims; the eventual consent judgment dismisses "all other claims and counterclaims by Handa or against Handa … WITH PREJUDICE," confirming their existence. I could not verify the precise answer filing date from the available sources; treat that date as unverified.

---

2. Pre-trial motions of substance

Venue/transfer (21-cv-00645): Handa moved to dismiss the claims against Handa Neuroscience under Fed. R. Civ. P. 12(b)(3) for improper venue and, alternatively, to transfer the entire case to the N.D. Cal. under 28 U.S.C. §§ 1404(a)/1406(a). After briefing and a 2022-01-24 teleconference, Judge Stark's Memorandum Opinion of 2022-03-01 (D.I. 47):

• Denied with prejudice the venue motion as to Handa Pharmaceuticals, Inc., Handa Pharma, Inc., and Handa Pharmaceuticals, LLC;
• Denied the transfer request;
• Denied without prejudice the dismissal request as to Handa Neuroscience, permitting Novartis venue-related discovery (including on whether Neuroscience was created to evade venue and on alter-ego/veil-piercing theories).

N.D. Cal. skirmishes (5:21-cv-03397): Novartis moved to stay the California case in favor of the first-filed Delaware case (motion hearing set 9/9/2021 before Judge Edward J. Davila), and Handa moved for judgment on the pleadings (D.I. 24, with reply briefing August 2021). The procedural resolution came when the California case was transferred to Delaware on 2022-03-21; the specific order or basis for the transfer was not verified in my sources.

Motion for reargument/leave for SJ (21-cv-00645): After the Federal Circuit's June 2022 invalidity ruling in the parallel HEC case (see § 6 below), Handa moved for reargument of its judgment-on-the-pleadings motion (D.I. 78) and, on 2022-06-28, requested leave to file a summary judgment motion as to the '405 patent, attaching the Federal Circuit opinion (D.I. 92 letter to Judge Maryellen Noreika). Novartis responded (D.I. 88; opposition letter). No SJ ruling issued before settlement.

---

3. Claim construction (Markman)

The case reached the claim-construction stage but no Markman ruling was ever issued:

• The parties exchanged claim-construction briefing and a Joint Claim Construction Chart (submitted ~2022-07-26 after extensions).
• 2022-07-27 — Judge Maryellen Noreika (to whom the case had been reassigned from Judge Stark) ordered the hearing narrowed to no more than 10 disputed terms, denied argument/decision on the remainder at the Markman stage, and permitted the parties to re-raise unaddressed terms in dispositive-motion briefing (order referencing D.I. 114 in 1:21-cv-00645 and D.I. 152 in the coordinated case 1:20-cv-00133).
• After reassignment to Judge Gregory B. Williams, the Markman hearing was rescheduled from 2022-10-06 to 2022-10-27 (oral order, D.I. 174), and the parties were directed to file an amended joint claim-construction chart (oral orders 2022-09-22 and 2022-09-29, D.I. 175, 179). The hearing never occurred — the case settled on 2022-10-24, two days before the rescheduled date.

---

4. Discovery milestones with strategic significance

• Venue-related discovery was expressly contemplated by Judge Stark's 2022-03-01 opinion (dismissal of Neuroscience denied "without prejudice to renew upon completion of venue-related discovery"), targeting the Handa entity structure.
• Invalidity contentions exchange (2022): Handa served invalidity contentions on the '405 and '179 patents; Novartis served responses in May 2022 (D.I. 75, 2022-05-17), Handa served Final Invalidity Contentions (June 2022), and Novartis served responses to the final contentions on 2022-07-18.
• 2022-07-28 — Novartis noticed Rule 30(b)(6) depositions of all four Handa entities (sealed notice), signaling fact discovery on infringement and the corporate relationship.
• October 2022 dispute — The parties sought a discovery conference (letter of 2022-10-10); Judge Williams scheduled a teleconference and set expedited letter briefing (order of 2022-10-12, D.I. 182). This dispute was mooted by settlement.
• The most strategically significant "discovery-adjacent" event was external: the Federal Circuit's June 2022 reversal holding the '405 patent invalid in HEC Pharm (see § 6), which drove Handa's summary-judgment push and the court's conditional dismissal order.

---

5. Trial, verdict, post-trial motions

None. No jury demand was made (DocketAlarm: "Jury Demand None"). The case never went to trial, and there was no verdict, no JMOL, no new-trial motion, and no fee award. The only "post-trial" relief is the consent judgment entered as part of the settlement.

---

6. Parallel proceedings and their effect on the litigation

*Federal Circuit — Novartis Pharms. Corp. v. HEC Pharm Co., Appeal No. 2021-1070 (the '405 patent's test case):* This related ANDA appeal over the same '405 patent directly shaped the Handa case:

• 2022-01-03 — A CAFC panel affirmed the D. Del.'s validity finding for the '405 patent (written-description challenge rejected).
• June 2022 (reported as 2022-06-22) — On HEC's petition for rehearing, a modified panel reversed, holding the '405 patent invalid for lack of written description (the "non-loading dose"/0.5 mg daily dosing claims). See Novartis press materials and Taiwan IP reporting; case citation HEC Pharm Co. v. Novartis Pharms. Corp., 55 F.4th 1366 (Fed. Cir. 2022) — the exact F.4th citation is from memory and should be double-checked.
• 2022-09-21 — The Federal Circuit denied rehearing en banc (Novartis announcement; Synapse/Patsnap).
• 2022-09-29 — The U.S. Supreme Court stayed the Federal Circuit's mandate after Novartis sought further review (letter filed in 21-cv-00645, D.I. 180, 2022-10-03, re "U.S. Supreme Court's September 29, 2022 Order Staying the Federal Circuit's Mandate").

Effect on the Handa litigation: On 2022-09-22, Judge Williams ordered the parties to "meet and confer and file a stipulation dismissing the claims of the '405 patent" within 48 hours after the Federal Circuit's mandate issued in No. 2021-1070 (oral order, D.I. 176). The Supreme Court's 2022-09-29 stay suspended that mandate, keeping the '405 claims alive — and within roughly three weeks the parties settled. Had the mandate issued, the '405 claims would have been dismissed in the Handa cases as well. The eventual settlement therefore occurred with the '405 patent still presumptively valid in the Handa litigation but under a cloud from the CAFC's HEC ruling.

PTAB IPR/PGR: I was unable to verify any PTAB IPR or PGR instituted on the '405 patent in this session (including any petition by Handa or HEC). The '405 patent's validity was litigated in district court/CAFC rather than through a verified IPR in my sources. This remains an open item to confirm via PTAB API/Unified Patents if precision is required.

---

7. Settlement, dismissal, judgment — final disposition

• 2022-10-24 — Novartis and Handa signed a confidential Settlement and License Agreement (Handa Taiwan Stock Exchange announcement, 2022-10-25; "fact date" 10/24/2022 U.S. time). Novartis agreed to withdraw all related suits and terminate the case; Handa agreed to pay Novartis royalties as a percentage of net sales of TASCENSO ODT under certain conditions (terms confidential). Handa publicly stated the settlement was intended to accelerate TASCENSO ODT's U.S. entry (marketed through Handa's licensee Cycle Pharmaceuticals Ltd.).
• 2022-10-24 — The parties lodged a [Proposed] Consent Judgment and Order of Injunction in both Delaware cases (1:21-cv-00645-GBW and 1:22-cv-00352-GBW), providing:
  • Judgment that use of the NDA 214962 product would infringe all asserted claims of the '405 and '179 patents;
  • Handa's stipulations of validity, enforceability, and infringement of the asserted claims;
  • A determination that the order is a "consent decree" under 21 U.S.C. § 355(c)(3)(C)(i)(II), so FDA final approval of NDA 214962 could be granted on entry (TASCENSO ODT had received only tentative FDA approval on 2021-10-18);
  • Dismissal with prejudice of all other claims and counterclaims;
  • An injunction barring U.S. commercial distribution before the "Generic Entry Date" set in the confidential settlement agreement;
  • The court retaining jurisdiction over settlement disputes; each party bearing its own costs and fees; and an express waiver of appeal.
• 2022-10-26 — Both Delaware cases were terminated/closed (DocketAlarm for 1:22-cv-00352; drugpatentwatch for 1:21-cv-00645: "Date Terminated 2022-10-26"). The N.D. Cal. case had been resolved by the transfer.
• No appeal — The parties waived appeal in the consent judgment; no appeal was filed.

---

8. Present posture

Closed/terminated. The case is fully resolved by settlement and consent judgment; no further proceedings are pending in the district court (the court retained only residual jurisdiction over settlement-agreement disputes). The principal post-settlement development was regulatory/commercial: Handa moved to convert TASCENSO ODT's tentative approval to final approval and launch in the U.S. under its license. If your file requires the exact final FDA approval date or the "Generic Entry Date," those are confidential and not publicly verified here.

---

Source-confidence notes

• Well-sourced: Complaint/parties/patents (RPX insight documents; paragraphfour consent-judgment PDFs); venue opinion of 2022-03-01 (D.I. 47, Justia/CourtListener); claim-construction order of 2022-07-27 and September–October 2022 oral orders (CourtListener docket feed); settlement announcement of 2022-10-25 (Handa Taiwan filings via multiple news aggregators); case termination 2022-10-26 (DocketAlarm; drugpatentwatch); CAFC timeline for the '405 patent (Novartis press releases, Nasdaq, Synapse/Patsnap).
• Partially verified / caution flags: the exact date of Handa's answer; the specific order effectuating the N.D. Cal.–to–Delaware transfer; the exact F.4th citation for the CAFC rehearing decision; and any PTAB IPR/PGR activity on the '405 patent — none of these could be confirmed from the sources available in this session and should be verified against PACER/PTAB before relying on them for filing purposes.

Based on my research (docket aggregators, the consent judgment filing, court opinions in the parallel Gilenya/'405 patent litigations, and firm bios), here is the plaintiff's counsel picture for Novartis Pharmaceuticals Corp. v. Handa Pharmaceuticals, Inc., No. 1:22-cv-00352 (D. Del.).

Preliminary docket context (important): The case began as Novartis's "safety suit" in the Northern District of California (No. 5:21-cv-03397, filed 5/6/2021), was transferred to D. Del. and docketed as 1:22-cv-00352 on 3/21/2022, then associated with lead case No. 1:21-cv-00645-MN (later reassigned to Judge Gregory B. Williams). The case closed 10/26/2022 via a stipulated consent judgment and injunction (proposed judgment dated 10/24/2022) covering the '405 patent (and '179 patent). The same Gibson Dunn/McCarter & English team handled the lead Delaware case.

Plaintiff's counsel of record

Delaware local counsel (McCarter & English LLP, Wilmington)

• Daniel M. Silver — Local/Delaware lead counsel (Del. Bar No. 4758). McCarter & English LLP, 405 N. King St., 8th Floor, Wilmington, DE. He signed the October 2022 consent judgment and filed the substantive papers in both 1:22-cv-00352 and lead case 1:21-cv-00645 (e.g., claim-construction submissions, notices of service). He is a veteran Delaware Hatch-Waxman litigator and was counsel of record for Novartis in the related Gilenya/'405 litigation Novartis Pharm. Corp. v. Accord Healthcare Inc., No. 18-1043 (D. Del.), which produced the 2020 trial decision and permanent injunction on the same '405 patent.
• Alexandra M. Joyce — Local/Delaware counsel. McCarter & English LLP, Wilmington (identified as McCarter & English in the Accord Healthcare opinions; she was the docket filer of Novartis's pro hac vice motions in 1:22-cv-00352 and of numerous discovery papers in the lead case). Also on the Accord Healthcare '405 trial team.
• Benjamin A. Smyth — Local/Delaware counsel (Del. Bar No. 5528). McCarter & English LLP, Wilmington. Co-signed the proposed consent judgment and order of injunction with Silver.

Lead/out-of-state counsel (Gibson, Dunn & Crutcher LLP — admitted pro hac vice May 2022)

The 5/13/2022 order (D.I. 98) granted Novartis's motion for pro hac vice admission of the Gibson Dunn team; Ranney, Blythe, and Huang were added for noticing on 5/17/2022.

• Jane M. Love, Ph.D. — Lead counsel (pro hac vice). Gibson Dunn, 200 Park Ave., New York, NY. She has been Novartis's lead outside counsel on the '405/Gilenya patent portfolio for years: lead counsel for Novartis AG in IPR2017-01550 (the IPR on U.S. Pat. No. 9,187,405), of counsel in Novartis v. Accord Healthcare (D. Del.), and counsel for Novartis in the Federal Circuit appeals (e.g., 24-2194). A registered patent attorney (Reg. No. 42,812) with a Ph.D., focused on pharmaceutical Hatch-Waxman litigation.
• Robert W. Trenchard — Co-lead/partner (pro hac vice). Gibson Dunn, New York. Long-time Novartis Hatch-Waxman partner on the Gilenya/'405 matters (IPR2017-01550, Accord Healthcare, and the N.D. Cal./D. Del. Handa actions). ~30 years' litigation experience.
• Andrew P. Blythe — Pro hac vice. Gibson Dunn, 333 S. Grand Ave., Los Angeles, CA. Listed as of counsel for Novartis in the Accord Healthcare '405 patent opinions; handles complex pharma patent litigation.
• Christine L. Ranney — Pro hac vice. Gibson Dunn, 1801 California St., Denver, CO. Also listed as of counsel for Novartis in the Accord Healthcare '405 opinions.
• Anne Y. Brody — Pro hac vice. Gibson Dunn, Of Counsel, Orange County (Irvine) office, 3161 Michelson Dr. Ph.D. chemist and USPTO-registered attorney; bio highlights representation of a global pharmaceutical company in consolidated Hatch-Waxman litigation on a lower-dose formulation, with judgment affirmed by the Federal Circuit (consistent with this Gilenya 0.5 mg litigation).
• Aileen C. Huang — Pro hac vice. Gibson Dunn (office not independently verified from my sources; admitted per D.I. 98 in 1:22-cv-00352).
• Sung Bin Lee — Pro hac vice. Gibson Dunn (office not independently verified; admitted per D.I. 98).
• Emil N. Nachman — Pro hac vice. Gibson Dunn (office not independently verified; admitted per D.I. 98).

Notes and caveats

• Yu-Chieh Hsin was the e-filing attorney who filed the corrected complaint in the transferor N.D. Cal. action (5:21-cv-03397) and the early N.D. Cal. docket entries; I could not independently verify Hsin's firm from the sources available, so I have not assigned one. (The N.D. Cal. filings were made in the same Gibson Dunn representation pattern, but that is inference, not a confirmed fact.)
• In-house counsel: No Novartis in-house attorney appears as counsel of record on the docket materials I located; the record reflects outside counsel only.
• Filings sealed: The parties' settlement agreement is confidential; the consent judgment itself is public. The docket reflects standard sealed discovery filings (infringement/invalidity contentions), but the counsel-of-record entries are public.
• All attorney names above (except Huang, Lee, Nachman, and Hsin, whose firm/office details could not be independently verified) are confirmed from the Unicourt docket summary for 1:22-cv-00352, the proposed consent judgment PDF (paragraphfour.com), the Novartis Pharm. Corp. v. Accord Healthcare Inc., No. 18-1043 (D. Del. Dec. 15, 2020) opinion (Casetext), the Gibson Dunn attorney bio for Brody, and PTAB filings in IPR2017-01550.

Bottom line: Novartis was represented by a Gibson Dunn (NY/LA/Denver/Orange County) national team led by Jane M. Love, Ph.D. and Robert W. Trenchard, with Delaware local counsel Daniel M. Silver, Alexandra M. Joyce, and Benjamin A. Smyth of McCarter & English LLP, Wilmington.

Defendant Counsel of Record — Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al., No. 1:22-cv-00352-GBW (D. Del.)

Context for the docket. This case was originally filed in the Northern District of California on May 4, 2021 (N.D. Cal. No. 5:21-cv-03397) and transferred to the District of Delaware on March 21, 2022, where it was opened as 1:22-cv-00352 before Judge Gregory B. Williams. The four defendants — Handa Neuroscience, LLC, Handa Pharmaceuticals, Inc., Handa Pharma, Inc., and Handa Pharmaceuticals, LLC — were jointly represented. The case settled; a [Proposed] Consent Judgment and Order of Injunction (dated Oct. 24, 2022) was filed in the Delaware case, and the docket reflects termination on Oct. 26, 2022. The signature block on that consent judgment is the most complete public listing of defense counsel of record (paragraphfour.com copy of D.I. in 1:22-cv-00352-GBW; DocketAlarm/UniCourt summaries).

Lead / out-of-state counsel — Husch Blackwell LLP

Don J. Mizerk — Lead counsel (partner, Husch Blackwell LLP, Chicago, IL).

• Signed the consent judgment as "Attorney for Defendants" and was the primary filer for the Handa entities throughout the N.D. Cal. phase (e.g., reply briefs in support of motion for judgment on the pleadings, oppositions, and statements opposing Novartis's notices, all filed by "Mizerk, Donald" on the N.D. Cal. docket before transfer).
• Experience: One of the most active ANDA (Hatch-Waxman) defense litigators in the country; per Husch Blackwell's own announcement, he "led successful defenses of … Handa Pharmaceuticals' novel orally-disintegrating tablet version of Novartis' Gilenya" (i.e., this very litigation), led a trial team defending Sigmapharm against Takeda's Trintellix® patent suit (2021), and represented Handa Oncology against Bristol-Myers Squibb's Sprycel® patent case. Named to Crain's Chicago Business "Notable Litigators and Trial Attorneys" (2023).

Matthew M. Kamps — Of counsel on the defense team (Husch Blackwell LLP, Chicago, IL).

• Listed alongside Mizerk in the defense signature block of the proposed consent judgment in this case. IP litigator at Husch Blackwell focused on patent/ANDA disputes; no additional notable public case history specific to this matter was verified beyond the Handa engagement.

Dustin L. Taylor — Of counsel on the defense team (Husch Blackwell LLP, Denver, CO).

• Also listed in the defense signature block of the proposed consent judgment. Denver-based IP litigator at Husch Blackwell; details of other notable matters were not independently verified from the available sources.

Local (Delaware) counsel — Phillips McLaughlin & Hall, P.A.

John C. Phillips, Jr. — Local counsel / lead Delaware counsel (Phillips McLaughlin & Hall, P.A., Wilmington, DE; Delaware Bar No. 110).

• Filed and signed the principal defense papers in the Delaware actions (e.g., the Rule 7.1 disclosure statements, motion to dismiss/transfer papers in the parallel D. Del. case 1:21-cv-00645, and the consent judgment in 1:22-cv-00352). UniCourt's attorney listing for 1:22-cv-00352 shows Phillips as the recorded defense attorney of record on the CM/ECF docket, consistent with D. Del. LR 83.5(d) requiring Delaware counsel to be the registered CM/ECF filers.
• Experience: Longstanding Delaware patent/Hatch-Waxman litigator; represents generic/pharma defendants in Delaware ANDA cases.

David A. Bilson — Local counsel (Phillips McLaughlin & Hall, P.A., Wilmington, DE; Delaware Bar No. 4986).

• Co-signed defense filings with Phillips, including the redacted opening briefs in the related D. Del. case and the consent judgment signature block in 1:22-cv-00352. Delaware IP litigator with a substantial docket of ANDA/patent cases in D. Del.

In-house counsel

• None identified. No Handa in-house attorney appeared on the public docket entries, pro hac vice motions, or the consent judgment signature block reviewed here. (Handa's parent, Handa Pharmaceuticals, Inc., is a Taiwanese company; its Taiwanese regulatory announcements reference retaining U.S. counsel but name no in-house litigator of record.)

Caveats

• The case terminated by settlement (consent judgment entered ~Oct. 26, 2022), so the above reflects counsel of record as of the close of the case.
• UniCourt's docket summary lists only John C. Phillips, Jr. as the defense attorney for the transferred Delaware case — that appears to be an incomplete CM/ECF snapshot; the consent judgment signature block confirms the full Husch Blackwell/Phillips McLaughlin & Hall team above.
• I could not verify from public sources whether any additional Husch Blackwell associates appeared pro hac vice in the Delaware case (the N.D. Cal. transfer file shows Mizerk as the primary filer, and the Delaware local counsel filed the rest). No sealed filings concealed the identity of counsel; the substantive settlement terms are confidential, but counsel identities are not.

Key sources: [Proposed] Consent Judgment, C.A. No. 1:22-cv-00352-GBW (paragraphfour.com copy); UniCourt case page for 1:22-cv-00352; DocketAlarm case page (1:22-cv-00352, terminated Oct. 26, 2022, Judge Williams); Unified Patents portal (N.D. Cal. transfer docket entries by "Mizerk, Donald"); Husch Blackwell news release ("Don Mizerk Named to Notable Litigators & Trial Attorneys List," 2023); related D. Del. case 1:21-cv-00645 docket (Phillips/Bilson filings).